PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
17.83
-0.18 (-0.97%)
Oct 10, 2025, 11:18 AM EDT - Market open
PureTech Health Revenue
PureTech Health had revenue of $1.85M in the half year ending June 30, 2025, a decrease of -41.24%. This brings the company's revenue in the last twelve months to $6.39M, up 1,265.60% year-over-year. In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth.
Revenue (ttm)
$6.39M
Revenue Growth
+1,265.60%
P/S Ratio
67.39
Revenue / Employee
$114,125
Employees
56
Market Cap
430.72M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRTC News
- 11 days ago - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF - Business Wire
- 6 weeks ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - PureTech Health plc – Half-Year Report - Business Wire
- 7 weeks ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 7 weeks ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 2 months ago - PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint - Business Wire
- 2 months ago - PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases - Business Wire
- 3 months ago - PureTech Announces Leadership Transition - Business Wire